top of page

News

Delaware – June 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of Oncology and Central Nervous system (CNS) compounds, announced today that Dr. Katrin Rupalla, PhD, MBA, is joining iQure’s Board of Directors.

Dr. Rupalla has vast experience in research and drug development with positions in various small, mid size and large Pharmaceutical Companies. She is currently Senior Vice President of Global Regulatory Affairs, Medical Documentation and R&D Quality at Lundbeck S/A in Copenhagen, Denmark.

About Dr. Rupalla:

Dr. Katrin Rupalla has more than 25 years experience in research & drug development, primarily in the areas of oncology, immunology and neurology. She is currently SVP, Global Head of Regulatory Affairs, Medical Documentation & R&D Quality at Lundbeck, Copenhagen, Denmark. Prior to joining Lundbeck, Dr. Rupalla worked in several leadership positions at Bristol-Myers Squibb, including as VP, Global Head of Regulatory Oncology based in Princeton, NJ, US and VP, Head of Development China based in Shanghai. Her Regulatory and Drug Development career includes several world-wide approvals of major products, such as REVLIMID®, OPDIVO® and YERVOY®, in the US, Europe and China as well as a multitude of new indication approvals. Dr. Rupalla is a certified pharmacist and obtained her PhD from Philipps University of Marburg, Germany in Pharmacology and Neurobiology and did postgraduate work in CNS Pharmacology at the University of Aachen/Novartis before starting her career in Drug Development at Roche.

Pawel Zolnierczyk, Chief Executive Officer:

We are delighted that Katrin has decided to join our Board and will help supervise our portfolio and development efforts. This is a great step forward for iQure, as Katrin’s expertise in regulatory affairs, oncology and neurology will be instrumental in iQure achieving critical project milestones that will enable us to continue to reach our key value inflection points.  

Delaware – May, 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of new therapeutics, recently secured an additional private investment of $50 000.

Company is pleased to confirm that it secured funding of $50,000 as a convertible loan from life sciences business angels. Under the agreement company will deploy proceeds to continue its business operational activities. Investing parties are individuals engaged into health and new therapeutics businesses.

Pawel Zolnierczyk, Chief Executive Officer:

We are delighted that our individuals from our sector have decided to invest into iQure Pharma. This is great and represent high level of trust into company and its prospect. Secured funding will be important and will allow Company to co-invest with prospective investors into our Neuropathic Pain portfolio. iQure Pharma is looking to continue its efforts to secure portfolio of promising therapeutics and funding required to progress with its development.

Delaware – April 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of Oncology and Central Nervous System (CNS) compounds, announced today that Professor Thomas Rades is joining the company to serve as Advisor for technical development and drug delivery for the entire iQure portfolio.

Prof. Rades has vast experience in technical development and drug delivery gained over more than 25 years in industry and academic research. He is currently holding the position of Research Chair in Pharmaceutical Design and Drug Delivery at the University of Copenhagen in Denmark.

About Professor Rades

Prof. Thomas Rades graduated with a Master’s in Pharmacy from the University of Hamburg, Germany, and obtained his PhD at the Technical University of Braunschweig, Germany. Prof. Rades has spent time in the industry at F. Hoffmann – La Roche in Switzerland and in academic research mostly in New Zealand and Denmark, where he collaborated successfully with colleagues across the globe. In 2014, he received an honorary doctorate from Åbo Academi University, Turku, Finland.

Prof. Rades has developed an international reputation for his research in the physical characterization of drugs in solid dosage forms as well as in vaccine delivery using nanoparticulate systems (both polymeric and lipid based). Prof. Rades has published more than 400 papers in international peer review journals as well as several book chapters, one book and applied for more than 14 patents.

His key research interests are in formulation and drug delivery and the physical characterizations in both solid and liquid crystalline matter. His research in both areas aims to improve drug therapy through appropriate formulation of medicines and to increase the understanding of the physico-chemical properties of drugs and medicines, which combines physical, chemical, and biological sciences and technology to optimally formulate drugs for use in humans as well as animals.

Dr. Peter Schiemann, Chairman of the Board: We are delighted that Thomas has decided to join our team and will help supervise our technical development activities, especially in drug delivery. This is a great step forward for iQure, as Thomas will be instrumental in helping the company make the right decisions when it comes to developing the right formulations for its APIs. Especially today with more sophisticated APIs, the right formulation can determine the difference between success and failure. iQure is looking forward to moving its compounds into development later this year, hoping to make a significant difference in patients’ lives.

JPM Week
No Abuse
bottom of page